Industry News
Biotechnology Industry News
Bial has stopped development in a…
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
GSK has struck a deal to buy…
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers.
Looking to spark an antibody-like…
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its foundational platform.
As costs climb, capital tightens…
As costs climb, capital tightens and AI enthusiasm accelerates, biopharma leaders are rethinking how better decisions get made.
Treeline Biosciences, an…
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Treeline has announced plans to merge with
Johnson & Johnson has paid $1…
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Incyte has struck a deal to buy a…
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of Bill Meury’s time as CEO, covers a late-phase bleeding disorder drug candidate that could
GSK’s latest hepatology…
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?
Roche is paying Nurix Therapeutics…
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
A deeper dive into survodutide’s…
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Even as Zepbound fires on all…
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early
On the heels of a strong showing…
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
As the American Diabetes…
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive
When it comes to turning T-cell…
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
Affibody may not have expected to…
Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to showcase the inflammation drug’s potential to prospective partners.
Longtime FDA leader Lola…
Longtime FDA leader Lola Fashoyin-Aje, M.D., is adapting to a new role at AstraZeneca as vice president and head of cell therapy regulatory science and strategy. Fashoyin-Aje is well-positioned to help the British pharma giant
On Thursday, the public had the…
On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency leader Marty Makary, M.D.
A stimulator of thyroid hormone…
A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar disorder, positioning its maker Autobahn Therapeutics to speed ahead to late-stage testing.
Two federal lawmakers have…
Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology.
Parabilis Medicines is gearing up…
Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect.